Idiopathic pulmonary fibrosis
FJ Martinez, HR Collard, A Pardo, G Raghu… - Nature reviews Disease …, 2017 - nature.com
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …
The lung in rheumatoid arthritis: focus on interstitial lung disease
P Spagnolo, JS Lee, N Sverzellati… - Arthritis & …, 2018 - Wiley Online Library
Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid
arthritis (RA) and is associated with significant morbidity and mortality. In addition …
arthritis (RA) and is associated with significant morbidity and mortality. In addition …
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
Pirfenidone: molecular mechanisms and potential clinical applications in lung disease
SM Ruwanpura, BJ Thomas… - American journal of …, 2020 - atsjournals.org
Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
[HTML][HTML] Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
LH Lancaster, JA de Andrade, JD Zibrak… - European respiratory …, 2017 - Eur Respiratory Soc
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind …
J Behr, SD Nathan, WA Wuyts, NM Bishop… - The Lancet …, 2021 - thelancet.com
Background The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis
(IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or …
(IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or …
An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)
U Costabel, C Albera, LH Lancaster, CY Lin, P Hormel… - Respiration, 2017 - karger.com
Abstract Background: RECAP (NCT00662038) was an open-label extension study in
patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of …
patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of …
Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
S Jouneau, B Crestani, R Thibault, M Lederlin… - Respiratory …, 2020 - Springer
Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
LC Li, LD Kan - Journal of ethnopharmacology, 2017 - Elsevier
Ethnopharmacological relevance Pulmonary fibrosis (PF) is a chronic, debilitating and often
lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with …
lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with …
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
A Caminati, C Lonati, R Cassandro… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …